Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
10.58
-0.23 (-2.13%)
Sep 10, 2026, 4:00 PM EDT - Market closed
Vir Biotechnology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 303.23 | 65.17 | 71.86 | 84.07 | 1,616 | 1,095 |
Other Revenue | - | 3.39 | 2.34 | 2.11 | - | - |
| 303.23 | 68.56 | 74.21 | 86.18 | 1,616 | 1,095 | |
Revenue Growth | 1495.93% | -7.61% | -13.89% | -94.67% | 47.50% | 1334.39% |
Cost of Revenue | 483.31 | 444.5 | 492.79 | 572.83 | 620.97 | 513.87 |
Gross Profit | -180.09 | -375.95 | -418.59 | -486.65 | 994.83 | 581.54 |
Selling, General & Admin | 99.38 | 92.07 | 119.03 | 174.44 | 161.76 | 160.79 |
Operating Expenses | 99.38 | 92.07 | 119.03 | 174.44 | 161.76 | 160.79 |
Operating Income | -279.47 | -468.02 | -537.62 | -661.09 | 833.07 | 420.75 |
Interest & Investment Income | 33.32 | 40.24 | 71.81 | 86.99 | 28.09 | 0.44 |
Other Non Operating Income (Expenses) | -1.27 | -0.41 | -2.22 | -8.99 | 4.26 | -9.44 |
EBT Excluding Unusual Items | -247.42 | -428.19 | -468.03 | -583.09 | 865.42 | 411.75 |
Merger & Restructuring Charges | - | 0.18 | -35 | -13.56 | - | - |
Gain (Loss) on Sale of Investments | -3.16 | 1.73 | -5.53 | -21.89 | -111.14 | 138.05 |
Asset Writedown | - | - | -14.55 | -9.66 | - | - |
Other Unusual Items | -0.72 | -11.49 | - | - | - | - |
Pretax Income | -251.3 | -437.77 | -523.11 | -628.19 | 754.28 | 549.8 |
Income Tax Expense | 0.38 | 0.22 | -1.15 | -13.08 | 238.44 | 21.22 |
Earnings From Continuing Operations | -251.68 | -437.99 | -521.96 | -615.12 | 515.84 | 528.58 |
Minority Interest in Earnings | - | - | - | 0.06 | - | - |
Net Income | -251.68 | -437.99 | -521.96 | -615.06 | 515.84 | 528.58 |
Net Income to Common | -251.68 | -437.99 | -521.96 | -615.06 | 515.84 | 528.58 |
Net Income Growth | - | - | - | - | -2.41% | - |
Shares Outstanding (Basic) | 148 | 139 | 136 | 134 | 133 | 130 |
Shares Outstanding (Diluted) | 148 | 139 | 136 | 134 | 135 | 133 |
Shares Change | 8.01% | 1.67% | 1.58% | -0.50% | 1.03% | 11.98% |
EPS (Basic) | -1.70 | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 |
EPS (Diluted) | -1.70 | -3.16 | -3.83 | -4.59 | 3.83 | 3.96 |
EPS Growth | - | - | - | - | -3.28% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -203.59 | -396.61 | -453.65 | -800.36 | 1,595 | -69.41 |
Free Cash Flow Per Share | -1.37 | -2.86 | -3.33 | -5.97 | 11.83 | -0.52 |
Gross Margin | -59.39% | - | - | - | 61.57% | 53.09% |
Operating Margin | -92.16% | -682.68% | -724.51% | -767.10% | 51.56% | 38.41% |
Profit Margin | -83.00% | -638.88% | -703.40% | -713.69% | 31.92% | 48.25% |
Free Cash Flow Margin | -67.14% | -578.52% | -611.35% | -928.71% | 98.73% | -6.34% |
EBITDA | -267.96 | -456.34 | -523.06 | -641.64 | 839.85 | 426.56 |
EBITDA Margin | -88.37% | - | - | - | 51.98% | 38.94% |
D&A For EBITDA | 11.51 | 11.68 | 14.56 | 19.45 | 6.78 | 5.81 |
EBIT | -279.47 | -468.02 | -537.62 | -661.09 | 833.07 | 420.75 |
EBIT Margin | -92.16% | - | - | - | 51.56% | 38.41% |
Effective Tax Rate | - | - | - | - | 31.61% | 3.86% |
Revenue as Reported | 303.23 | 68.56 | 74.21 | 86.18 | 1,616 | 1,095 |